Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

AN2 Therapeutics, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-21Dec-31-20
   S-1/AS-1/A
Operating expenses:    
General and administrative  4.71.3
    Total operating expenses  21.67.3
    Loss from operations  -21.6-7.3
Other income, net  0.0-6.3
    Net loss  -21.5-13.6
   
Net loss per share attributable to common stockholders, basic  ($10.64)($5.68)
Net loss per share attributable to common stockholders, diluted  ($10.64)($5.68)
   
Weighted-average number of shares used in computing net loss per share, basic  2.62.6
   
Other comprehensive loss:    

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy